INDOUS
UnclassifiedIndo Us Biotech Limited
₹66.69
+0.49(0.74%)
EMA 9: 66.89EMA 21: 68.84RSI: 43.9MACD: -2.21ATR: 5.01
Overlays
RSI (14)
Open
₹66.20
High
₹67.99
Low
₹65.87
Close
₹66.69
Volume
1,830
Indo Us Biotech Limited (INDOUS) last closed at ₹66.69 on 17 Nov 2026, 58.1% below its 52-week high. Price is below both the 50-day and 200-day averages. Volume in the last session was light, at 0.1 times the 20-day average. The scanner currently flags Downtrend Alignment.
1 week
+0.2%
1 month
-7.3%
3 months
-21.3%
52-week high
₹159
-58.1% from high
52-week low
₹57.5
Volume vs 20-day
0.05×
Active signals
Downtrend AlignmentBEARISH
Day 10 · since 02 Nov-1.9%
Signal history
| Dates | Signal | Type | Lasted | Quality | Move |
|---|---|---|---|---|---|
| 02 Nov | EMA Death Cross (9/21) | BEARISH | 1d | Q27 | — |
| 28 Oct | 20-Day High Breakout | BULLISH | 1d | Q54 | — |
| 28 Oct | RSI Momentum Expansion | BULLISH | 1d | Q54 | — |
| 26 Oct | RSI Oversold Zone | NEUTRAL | 1d | Q27 | — |
| 21 Oct | RSI Oversold Zone | NEUTRAL | 1d | Q20 | — |
| 28 Sept – 26 Oct | Downtrend Alignment | BEARISH | 17d | Q19 | -22.6% |
| 23 Sept – 24 Sept | Downtrend Alignment | BEARISH | 2d | Q14 | -0.1% |
| 18 Sept – 21 Sept | Downtrend Alignment | BEARISH | 2d | Q12 | +0.6% |
| 11 Sept – 16 Sept | Downtrend Alignment | BEARISH | 3d | Q17 | -1.4% |
| 24 Aug – 07 Sept | Downtrend Alignment | BEARISH | 10d | Q11 | -4.9% |
| 24 Aug – 25 Aug | EMA Death Cross (9/21) | BEARISH | 2d | Q11 | -1.0% |
| 20 Aug | EMA Crossover (9/21) | BULLISH | 1d | Q43 | — |
| 18 Aug – 19 Aug | 20-Day High Breakout | BULLISH | 2d | Q37 | -0.2% |
| 21 Jul – 12 Aug | Downtrend Alignment | BEARISH | 17d | Q16 | -6.2% |
| 15 Jul – 17 Jul | Downtrend Alignment | BEARISH | 3d | Q19 | +0.3% |
| 10 Jul | Downtrend Alignment | BEARISH | 1d | Q16 | — |
| 06 Jul – 08 Jul | Downtrend Alignment | BEARISH | 3d | Q11 | -1.8% |
| 29 Jun – 01 Jul | Downtrend Alignment | BEARISH | 3d | Q12 | -1.5% |
| 23 Jun – 24 Jun | Downtrend Alignment | BEARISH | 2d | Q26 | -0.8% |
Technical data for educational purposes only — not investment advice